Patents Assigned to UNIVERSITAT AUTÒNOMA DE BARCELONA
-
Patent number: 12146169Abstract: The present invention provides new polynucleotide sequences, adeno-associated virus-derived vectors and pharmaceutical compositions containing the same for the treatment of lysosomal storage disorders and specially, for the treatment of mucopolysaccharidosis type IVA or Morquio A syndrome.Type: GrantFiled: May 27, 2019Date of Patent: November 19, 2024Assignees: ESTEVE PHARMACEUTICALS, S.A., UNIVERSITAT AUTÓNOMA DE BARCELONAInventors: Maria Fátima Bosch Tubert, Victor Sanchez Clares, Albert Ribera Sanchez, Virginia A. Haurigot
-
Patent number: 12054779Abstract: The invention relates to a specific panel of circulating synaptic protein related miRNAs for use in the diagnosis of Mild Cognitive Impairment (MCI) and/or early diagnosis of Alzheimer's disease (AD). The invention also relates to a method and to a kit for the diagnosis of said diseases using said specific panel of circulating miRNAs biomarkers.Type: GrantFiled: June 13, 2019Date of Patent: August 6, 2024Assignees: Universitat Autònoma de Barcelona, Centro Investigacion Biomedica En Red Enfermedades Neurodegenerativas (CIBERNED)Inventors: Alfredo Jesus Miñano Molina, Dolores Siedlecki Wullich, Jose Rodriguez Alvarez
-
Patent number: 12036268Abstract: The invention discloses using secreted splicing variant of mammal Klotho (s-KL) as an agent for the prevention and/or treatment of cognitive and/or behaviour impairments. It also refers to gene constructs and expression vectors useful in gene therapy for the delivery of said s-KL variant to the central nervous system of a mammal, in particular a rodent or a human. Pharmaceutical compositions comprising either the protein s-KL or any gene construct for expressing the protein in the CNS are also disclosed.Type: GrantFiled: November 21, 2016Date of Patent: July 16, 2024Assignees: Universitat Autònoma De Barcelona, Fundació Institució Català de Recerca i Estudis AvançatsInventors: Miguel Chillon Rodriguez, Anna Masso Chacon, Assumpció Bosch Merino
-
Publication number: 20240107988Abstract: Described herein is a genetically modified plant or non-human animal having reduced expression of an endogenous target gene.Type: ApplicationFiled: January 27, 2022Publication date: April 4, 2024Applicants: UNIVERSITAT AUTÒNOMA DE BARCELONA, HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)Inventors: Maria Fátima BOSCH TUBERT, Verónica JIMENEZ CENZANO, Miquel GARCIA MARTINEZ, Estefanía CASANA LORENTE, Martin Matthias HRABE DE ANGELIS, Gerhard Kurt Herbert PRZEMECK, Anna-Lena AMEND
-
Patent number: 11943548Abstract: An apparatus and a method using no switching elements for multiplexing and reading arrays of sensors whose electrical resistance is modulated by the signals to be measured are proposed. Sensor elements are arranged in groups and columns where each column is fed with a continuous voltage waveform of different amplitude, frequency and phase characteristics which then produce current signals that are modulated by the variable resistance signals to be measured. Modulated currents are summed row-wise and collected at the read-out circuits, either by applying a constant voltage to each row of the array or by connecting a capacitor and converting these current summations into output voltage signals. The read-out circuits de-multiplex each individual sensor signal to be measured by lock-in demodulation according to the frequencies and phases employed for the stimulation of each column.Type: GrantFiled: August 2, 2019Date of Patent: March 26, 2024Assignees: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC), UNIVERSITAT AUTÒNOMA DE BARCELONA, FUNDACIÓ INSTITUT CATALÀ DE NANOCIÈNCIA I NANOTECNOLOGIA (ICN2), INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATSInventors: Anton Guimerà Brunet, Lluis Antoni Terés Terés, Michele Dei, Jose Agustín Cisneros Fernández, Francisco Serra Graells, José Antonio Garrido Ariza
-
Publication number: 20230346977Abstract: The present disclosure provides gene constructs containing a nucleic acid sequences encoding a mammalian s-KL, operatively linked to a muscle cell-specific promoter, for use in the treatment of motor impairment that may manifest, for example, in a neuromuscular disorder or disease, utilizing viral and non-viral vectors with muscle cell and motor neuron tropisms containing gene constructs containing a nucleic acid sequence encoding a mammalian s-KL, operatively linked to a promoter such as a muscle cell-specific promoter, is delivered in pharmaceutical compositions containing the expression vector, isolated cells containing the expression vector, and methods of treating motor impairment and motor neuron diseases.Type: ApplicationFiled: April 13, 2023Publication date: November 2, 2023Applicants: Universitat Autònoma de Barcelona, Consorcio Centro de Investigación Biomédica en Red, Institució Catalana de Recerca i Estudis Avançats, Fundació Hospital Universitari Vall d’Hebron-Institut de RecercaInventors: Assumpció Bosch Merino, Sergi Verdés Franquesa, Mireia Herrando Grabulosa, Xavier Navarro Acebes, Miguel Chillon Rodriguez
-
Publication number: 20230201306Abstract: Described herein is a gene construct comprising a nucleotide sequence encoding a fibroblast growth factor 21 (FGF21), for use in the treatment and/or prevention of a central nervous system (CNS) disorder or disease, or a condition associated therewith.Type: ApplicationFiled: May 26, 2021Publication date: June 29, 2023Applicant: Universitat Autònoma de BarcelonaInventors: Maria Fatima Bosch Tubert, Veronica Jiménez Cenzano, Ivet Elias Puigdomenech, Ignasi Grass Costa, Claudia Jambrina Pallarés, Victor Sacristan Fraile
-
Publication number: 20230160022Abstract: The present invention provides a method for determining the resistance of a microorganism to a drug by detecting at least a transcript of a drug resistance gene from a microorganism in a biological sample, the method comprising the steps of: (i) lysing the cells by means of a chemical or a mechanical method, thereby obtaining a lysate and cell debris; (ii) obtaining a ribosome-antibody complex from the lysate using an antibody or a fragment thereof which binds specifically to a microorganism-ribosomal protein; (iii) purifying the mRNA associated to the ribosome-antibody complex by means of a nucleic acid extraction method; and (iv) submitting the resulting mRNA to a specific gene detection method, thereby identifying the at least one drug resistance gene transcript of the biological sample.Type: ApplicationFiled: April 11, 2019Publication date: May 25, 2023Applicant: UNIVERSITAT AUTONOMA DE BARCELONAInventors: Albert QUINTANA ROMERO, Elisenda SANZ IGLESIAS
-
Publication number: 20230128889Abstract: The present invention concerns screening methods to identify compounds that regulate activity of RSH enzymes such as Rel, and specifically Rel synthetase and/or Rel hydrolase activity. Also intended are compounds that interact and regulate Rel synthetase and/or hydrolase activity. These compounds are valuable to target persister cells not affected by traditional antibiotics.Type: ApplicationFiled: March 30, 2020Publication date: April 27, 2023Applicants: Université Libre de Bruxelles, Universitat Autónoma de BarcelonaInventors: Abel GARCIA PINO, Cédric Pierre GOVAERTS, Hanna AINELO, Hedvig TAMMAN, Vasili HAURYLIUK, Leonardo PARDO CARASCO, Minos Timotheos MATSOUKAS
-
Patent number: 11629361Abstract: The present invention relates to adeno-associated viral vector useful for transducing adipose tissue. The invention also relates to polynucleotides, plasmids, vectors and methods for the production of such adeno-associated viral vector. The invention also relates to gene therapy methods useful for the treatment of a disease that requires the regulation of the expression levels of a gene.Type: GrantFiled: March 12, 2020Date of Patent: April 18, 2023Assignee: Universitat Autònoma de BarcelonaInventors: Verónica Jiménez Cenzano, Fátima Bosch Tubert
-
Patent number: 11590198Abstract: Conjugates comprising a targeting moiety specific for the CXCR4 and based on the polyphemusin-derived peptide and a therapeutic or imaging agent are provided. Therapeutic and diagnostic methods with the conjugates which require specific targeting to CXCR4+cells are provided as well.Type: GrantFiled: September 21, 2020Date of Patent: February 28, 2023Assignees: UNIVERSITAT AUTONOMA DE BARCELONA, INSTITUT RECERCA HOSPITAL DE LA SANTA CREU I SANT PAU, CENTRO DE INVESTIGACION BIOMEDICA EN RED EN BIOINGENIERIA BIOMATERIALES Y NANOMEDICINA (CIBER BBN)Inventors: Antonio Pedro Villaverde Corrales, Esther Vazquez Gomez, Maria Virtudes Cespedes Navarro, Isolda Casanova Rigat, Neus Ferrer Miralles, Ramon Mangues Bafalluy, Ugutz Unzueta Elorza
-
Patent number: 11583511Abstract: The present invention relates to maresins, preferably maresin-1, for use in the treatment of CNS injuries preferably selected from spinal cord injury and traumatic brain injury.Type: GrantFiled: July 20, 2017Date of Patent: February 21, 2023Assignees: UNIVERSITAT AUTONOMA DE BARCELONA, OHIO STATE UNIVERSITY, THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITYInventors: Ruben Lopez Vales, Isaac Francos Quijorna, Jan Markus Schwab, Samuel David
-
Patent number: 11529396Abstract: The invention provides compositions and methods useful for the treatment and prevention of conditions associated with short telomere length.Type: GrantFiled: August 4, 2015Date of Patent: December 20, 2022Assignees: FUNDACIÓN DEL SECTOR PÚBLICO ESTATAL CENTRO NACIONAL DL'INVESTIGACIONES ONCOLÓGICAS CARLOS III (F.S.P. CNIO), UNIVERSITAT AUTÓNOMA DE BARCELONAInventors: Maria Bobadilla, Ivan Formentini, Maria Antonia Blasco Marhuenda, Christian Baer, Fàtima Bosch I Tubert
-
Publication number: 20220395438Abstract: The present invention relates to a tooth whitening composition, which comprises a reducing agent partially encapsulated in liposomes. It relates also to a method for preparing that tooth whitening composition and to the non-therapeutic cosmetic use of that composition for tooth whitening.Type: ApplicationFiled: November 4, 2020Publication date: December 15, 2022Applicant: Universitat Autonoma de BarcelonaInventors: Manuel Valiente Malmagro, Maria Jesús Sánchez Martín, Clara Babot Marquillas, Jorge Rodríguez Martínez
-
Patent number: 11484520Abstract: The present invention relates to a specialized pro-resolving lipid mediator comprising maresins, D-series resolvins, E-series resolvins, protectins or lipoxins, or a combination thereof, for use in the treatment of neurodegenerative diseases and/or autoimmune diseases.Type: GrantFiled: January 17, 2018Date of Patent: November 1, 2022Assignee: UNIVERSITAT AUTONOMA DE BARCELONAInventors: Ruben Lopez Vales, Alba Sanchez Fernandez, Anna Martinez Muriana, Isaac Francos-Quijorna
-
Publication number: 20220226501Abstract: Described herein is a gene construct comprising a nucleotide sequence encoding insulin, for use in the treatment and/or prevention of neuroinflammation, neurodegeneration and/or cognitive decline, or a disease or condition associated therewith.Type: ApplicationFiled: May 29, 2020Publication date: July 21, 2022Applicant: Universitat Autònoma de BarcelonaInventors: Fàtima Bosch Tubert, Ivet Elias Puigdomenech, Albert Ribera Sánchez, Ignasi Grass Costa
-
Publication number: 20220202733Abstract: The invention relates to protein particles comprising a cluster of one or more types of assembled self-contained protein, wherein the particle has a size from 50 nm to 50 micrometers; is in form of a pellet in aqueous media; is mechanically stable; and it release a particular percentage by weight of the self-contained protein within a predetermined period of time, and any other compound contained in the particle. Particular methods for obtaining the particles are also disclosed, said methods comprising the addition of salts to allow precipitation of proteins. Particular protein particles comprising lipids associated with the assembly of self-contained proteins are also disclosed. The invention also relates to several uses of the particle, in particular medical uses and to pharmaceutical and cosmetic compositions comprising the particles.Type: ApplicationFiled: April 8, 2020Publication date: June 30, 2022Applicants: UNIVERSITAT AUTONOMA DE BARCELONA, INSTITUT RECERCA HOSPITAL DE LA SANTA CREU I SANT PAU, CONSORCIO CENTRO DE INVESTIGACIÓN BIOMÉDICA EN REDInventors: Antonio VILLAVERDE CORRALES, Esther VÁZQUEZ GÓMEZ, Héctor LÓPEZ LAGUNA, Julieta María SÁNCHEZ, Ramón MANGUES BAFALLUY, Patricia ALAMO
-
Patent number: 11338046Abstract: The present invention provides new adeno-associated virus-derived vectors and pharmaceutical compositions containing the same for the treatment of lysosomal storage disorders and specially, for the treatment of mucopolysaccharidoses Type IIID.Type: GrantFiled: September 22, 2017Date of Patent: May 24, 2022Assignees: ESTEVE PHARMACEUTICALS, S.A., UNIVERSITAT AUTÓNOMA DE BARCELONAInventors: Carles Roca Lecha, Virginia A. Haurigot-Mendonça, Fàtima Bosch Tubert
-
Patent number: 11270088Abstract: The present invention relates to a chipless RFID tag (T), comprising: —a dielectric substrate (1); and —electromagnetic resonators (3) excitable by an external electromagnetic field and respectively arranged on separate spatial locations of the dielectric substrate (1) forming a row, and configured to resonate at a common resonant frequency. The dielectric substrate (1) defines several predetermined encoding areas that include the separate spatial locations, so that data is encoded by the presence/absence of operative electromagnetic resonators (3) thereon. The present invention also relates to a system comprising the chipless RFID tag of the invention and a RFID reader (R) reading an encoded code by detecting the presence/absence of attenuation peaks on an electromagnetic wave providing the external electromagnetic field to the electromagnetic resonators (3). The present invention also relates to a method for encoding data on a chipless RFID tag defined according to the present invention.Type: GrantFiled: May 31, 2018Date of Patent: March 8, 2022Assignee: UNIVERSITAT AUTONOMA DE BARCELONAInventors: Juan Fernando Martín Antolín, Cristià Herrojo Prieto, Francisco Javier Mata Contreras, Ferran Paredes Marco
-
Patent number: 11261434Abstract: The invention provides compositions and methods useful for the treatment and prevention of conditions associated with myocardial infarction.Type: GrantFiled: August 4, 2015Date of Patent: March 1, 2022Assignees: Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO), Universität Autónoma de BarcelonaInventors: Maria Antonia Blasco Marhuenda, Bruno Bernardes De Jesus, Christian Baer, Rosa María Serrano Ruiz, Fàtima Bosch I Tubert, Eduard Ayuso, Ivan Formentini, Maria Bobadilla, Jacques Mizrahi